Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of direct-acting antivirals to treat infections worldwide. Its product candidates include vapendavir, which is in Phase IIb SPIRITUS trials for an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; and BTA074 that is in Phase II antiviral treatment for genital warts caused by human papillomavirus types 6 and 11. The company’s product candidates also comprises BTA585, an oral fusion protein inhibitor, which is in Phase I development for the treatment of respiratory syncytial virus (RSV) A and B infections; and laninamivir octanoate that is in Phase II development for a one-time, inhaled treatment of influenza A and B infections. It is also involved in a preclinical stage RSV non-fusion inhibitor program. Biota Pharmaceuticals, Inc. is headquartered in Alpharetta, Georgia.